Gastroenteropancreatic neuroendocrine tumors: Role of surgery

被引:4
作者
Sauvanet, Alain [1 ]
机构
[1] Univ Paris Diderot, Hop Beaujon, AP HP, Dept HPB Surg,PMAD, 100 Blvd Gen Leclerc, F-92110 Clichy, France
关键词
Gastroenteropancreatic neuroendocrine tumors; Pancreatectomy; Pancreatic insufficiency; Observation; LYMPH-NODE INVOLVEMENT; ENDOCRINE TUMORS; SURGICAL-MANAGEMENT; PANCREATIC INSUFFICIENCY; SHORT-TERM; RESECTION; SURVIVAL; CM; LYMPHADENECTOMY; METAANALYSIS;
D O I
10.1016/j.ando.2019.04.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Natural history of gastroenteropancreatic (GEP) Neuroendocrine tumors (NETs) is better and better known so indications of surgery are presently selective. Surgical resection, but also endoscopic resection and observation, can be proposed for gastric NETs according to presentation, size and grade. For small bowel NETs, resection is frequently needed but should obtain the best compromise between radicality and postoperative functional disorders. Appendiceal NETs are frequently diagnosed by appendectomy for appendicitis, but some patients at high risk for lymph node metastasis and recurrence should be reoperated for radical resection. Rectal NETs are often diagnosed incidentally; the smallest (< 1 cm) can be resected endoscopically but the most aggressive need a oncological proctectomy. Pancreatic NETs represent a wide spectrum, ranging from fully benign tumors to very aggressive ones. lnsulinomas are mostly benign, responsible for incapacitating symptoms despite medical treatment, and should ideally be treated by parenchyma sparing resection, mainly enucleation. Conversely, symptoms of gastrinomas are efficiently treated medically but their resection needs an oncological approach. Nonfunctioning PNETs are more and more frequently and incidentally discovered. According to their size, presentation and patient's characteristics, they need a resection (oncological or parenchyma-sparing) or a close observation. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 50 条
  • [41] Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances
    Mohamed, Amr
    Strosberg, Jonathan R.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (06) : 721 - 727
  • [42] New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future
    Cidon, Esther Una
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 9 (01) : 4 - 20
  • [43] The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors - A Single-Center Experience
    Tsai, Hui-Jen
    Hsiao, Chin-Fu
    Chang, Jeffrey S.
    Chen, Li-Tzong
    Chao, Ying-Jui
    Yen, Chia-Ju
    Shan, Yan-Shen
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Proposal of a treatment algorithm for the management of gastroenteropancreatic neuroendocrine tumors
    Bajetta, Emilio
    TUMORI, 2010, 96 (05) : 852 - 855
  • [45] Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing
    Panarelli, Nicole
    Tyryshkin, Kathrin
    Wong, Justin Jong Mun
    Majewski, Adrianna
    Yang, Xiaojing
    Scognamiglio, Theresa
    Kim, Michelle Kang
    Bogardus, Kimberly
    Tuschl, Thomas
    Chen, Yao-Tseng
    Renwick, Neil
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : 47 - 57
  • [46] Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems
    Flaum, Nicola
    Valle, Juan W.
    Mansoor, Wasat
    McNamara, Mairead G.
    FUTURE ONCOLOGY, 2016, 12 (22) : 2561 - 2578
  • [47] Liver Resection for Gastroenteropancreatic Neuroendocrine Tumors with Extrahepatic Disease
    Mahuron, Kelly M.
    Limbach, Kristen E.
    Hernandez, Matthew C.
    Ituarte, Philip H. G.
    Li, Daneng
    Kessler, Jonathan
    Singh, Gagandeep
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [48] Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
    Oberg, Kjell
    CLINICS, 2012, 67 : 109 - 112
  • [49] Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors
    Chi, Weiwei
    Warner, Richard R. P.
    Chan, David L.
    Singh, Simron
    Segelov, Eva
    Strosberg, Jonathan
    Wisnivesky, Juan
    Kim, Michelle K.
    PANCREAS, 2018, 47 (03) : 321 - 325
  • [50] Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors
    Paragliola, Rosa Maria
    Prete, Alessandro
    Papi, Giampaolo
    Torino, Francesco
    Corsello, Andrea
    Pontecorvi, Alfredo
    Corsello, Salvatore Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3459 - 3470